Trial Profile
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Etrolizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms BERGAMOT
- Sponsors Roche
- 01 Apr 2023 This trial has been Completed in Slovakia, According to European Clinical Trials Database record.
- 11 Oct 2022 Primary endpoint(Induction Phase: Percentage of Participants with Endoscopic Improvement at Week 14) has not been met according to Results presented at the 30th United European Gastroenterology Week.
- 11 Oct 2022 Primary endpoint (Induction Phase: Percentage of Participants with Clinical Remission at Week 14)has not been met according to Results presented at the 30th United European Gastroenterology Week.